News | Atrial Fibrillation | May 13, 2019

Noninvasive Ear-Clip Nerve Stimulation Suppresses Atrial Fibrillation

New approach could change how patients are treated for AFib

The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial.

The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial. 

May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce atrial fibrillation (AF) burden and showcases an emerging noninvasive treatment option for patients. The trial is the first to examine the effect of transcutaneous electrical vagus nerve stimulation on suppressing AF. The results of the late-breaking TREAT AF trial were presented at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

Device vagus nerve stimulation has been successfully implemented to treat epilepsy and is a treatment option approved by the U.S. Food and Drug Administration (FDA). About one third of people do not respond fully to anti-seizure drugs and nerve stimulation has become an option for these patients.[1] The Parasym Salustim device used in this trial uses transcutaneous vagus nerve stimulation (TVNS) through a small clip. The device is used for treating tinnitus, but this trial sought to better understand if this treatment option could work for patients suffering from AF.

"Our clinical trial introduces a novel self-administered, non-invasive therapy for patients newly diagnosed with atrial fibrillation. There are cases when drug therapy or surgery are not the optimal options, so this has the potential to serve as another approach for patients," said lead author Stavros Stavrakis, M.D., Ph.D., University of Oklahoma Health Sciences Center. "It was encouraging to see the significant reduction in AF burden and that the device was well received in terms of adherence rate. This approach opens the door to a new way of thinking about AF management and showcases that we can push boundaries to help advance patient care."

The TREAT AF trial is a sham-controlled, double-blind, randomized clinical trial designed to examine the effect of low-level transcutaneous electrical stimulation of the auricular branch of the vagus nerve at the tragus (LLTS) on AF burden over a six-month period. LLTS was delivered using an ear clip attached to either tragus (active; n=26) or the ear lobe (sham; n=27). The patients received individual training and used the device for one hour every day for six months. AF burden over two-week periods was assessed by noninvasive continuous ECG monitoring at baseline, three and six months and heart rate variability based on five minutes ECG readings and serum cytokines were measured at the respective time points. Baseline characteristics including age, gender and stroke risk were similar between the two groups.

Adherence to the stimulation protocol was 75 percent in the active arm and 83 percent in the sham arm. At six months, the median AF burden was reduced by 85 percent in the active arm compared to the sham. After combining across the three- and six-month time points, the median AF burden was reduced by 75 percent in the active arm compared to the sham arm.

The authors of this study call for trials in a multi-center setting with larger populations. Through additional research, the authors also hope to pinpoint exactly which patients would benefit the most from this therapy approach.

AF is the most common abnormal heart rhythm condition. It affects more than 33.5 million people around the world and this number is expected to continue to rise.[2] 

All the HRS 2019 late-breaking studies 

Link to other HRS 2019 news

1. Epilepsy Foundation. Vagus Nerve Stimulation. seizures-and-epilepsy/devices/vagus-nerve-stimulation-vns
Sumeet S. Chugh et al. Worldwide Epidemiology of Atrial Fibrillation. Circulation. 2014;129:837–847

Related Content

The Carmat system, an experimental artificial heart includes an autoregulation control mechanism, or Auto-Mode, that can adjust to the changing needs of patients treated for end-stage heart failure. Outcomes in the first series of patients managed with the new heart replacement pump in Auto-Mode are presented in the journal of the American Society for Artificial Internal Organs (ASAIO). 

The Carmat artificial heart technology.

News | Artificial Heart | June 23, 2021
June 18, 2021 – An experimental artif...
News | Artificial Heart | May 27, 2020
May 27, 2020 — Carmat, a developer of the of a next generation advanced total artificial heart, announces the first i
CorInnova Awarded 2017 InnoSTARS Prize for EpicHeart Soft Robotic Heart Assist Device
News | Artificial Heart | December 11, 2017
CorInnova Inc. recently announced it was awarded second prize in the “2017 InnoSTARS” life science competition for its...
CorInnova Awarded Seminal Patent for Minimally Invasively-Delivered Soft Robotic Heart Device
News | Artificial Heart | October 27, 2017
CorInnova Inc. announced it has received notice of allowance of a seminal patent to protect its intellectual property...
SynCardia, Chapter 11 reorganization, sale, Total Artificial Heart
News | Artificial Heart | September 13, 2016
August 29, 2016 — SynCardia Systems, manufacturer of the...
Carmat, bioprosthetic artificial heart, PIVOTAL study, first implantation, heart failure
News | Artificial Heart | September 09, 2016
Carmat announced that the first implantation of its bioprosthetic artificial heart within the framework of the PIVOTAL...
SynCardia Total Artificial Heart, TAH-t, documentary, Retro Reports, The New York Times
News | Artificial Heart | March 24, 2016
March 24, 2016 — A new documentary produced by Retro Report for The New York Times looks at the history and